Urology · Myrtle Beach, SC
NPI
1265423453
Since 2005
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
823 82nd Pkwy
Myrtle Beach, SC, 29572
Phone (843) 449-1010
Groups this clinician bills Medicare through
Medicare paid, 2024
$980K
27,418 services
Medicare patients, 2024
962
Average age 76
Drug cost, 2024
$6.9M
1,827 prescriptions
Company payments, 2025
$514K
From 48 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Neal Shore was code J9271 (injection, pembrolizumab, 1 mg), 6,800 times for 11 patients. In total Neal Shore billed 27,418 services in 101 codes, and Medicare paid $980K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-12-29.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 6,800 | 11 | $44.76 | $304K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 4,901 | 50 | $0.10 | $510 |
| J0897 Injection, denosumab, 1 mg | Office | 2,880 | 26 | $20.73 | $60K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,271 | 501 | $12.79 | $16K |
| 81001 Clinical Chemistry | Office | 1,080 | 548 | $3.09 | $3,333 |
| 99214 Office E&M - Established | Office | 777 | 357 | $97.17 | $76K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 750 | 11 | $2.27 | $1,702 |
| 84153 Clinical Chemistry | Office | 686 | 370 | $18.02 | $12K |
| 36415 Venipuncture Blood Collection | Office | 584 | 440 | $8.65 | $5,052 |
| 99212 Office E&M - Established | Office | 422 | 295 | $41.43 | $17K |
| 99213 Office E&M - Established | Office | 396 | 273 | $65.14 | $26K |
| 80048 Clinical Chemistry | Office | 312 | 155 | $8.29 | $2,586 |
| 80076 Clinical Chemistry | Office | 291 | 143 | $8.01 | $2,331 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 174 | 33 | $138.72 | $24K |
| 85025 Blood Count | Office | 135 | 77 | $7.61 | $1,027 |
By year: 2022 $850K for 32,543 services; 2023 $864K for 30,375 services; 2024 $980K for 27,418 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81001 Clinical Chemistry | 1,080 | 548 | $3.09 | $3,333 |
| 84153 Clinical Chemistry | 686 | 370 | $18.02 | $12K |
| 36415 Venipuncture Blood Collection | 584 | 440 | $8.65 | $5,052 |
| 80048 Clinical Chemistry | 312 | 155 | $8.29 | $2,586 |
| 80076 Clinical Chemistry | 291 | 143 | $8.01 | $2,331 |
| 85025 Blood Count | 135 | 77 | $7.61 | $1,027 |
| 85027 Blood Count | 22 | 20 | $6.34 | $139 |
| 83615 Clinical Chemistry | 11 | 11 | $5.92 | $65.12 |
Medicare prescription drug claims, 2024
In 2024, the drug Neal Shore prescribed most often to Medicare patients was Tamsulosin Hcl, with 302 prescriptions and refills. In total Neal Shore wrote 1,827 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 302 | 838 | 107 | $5,441 |
| Orgovyx Relugolix | 249 | 257 | 44 | $661K |
| Finasteride Generic | 171 | 491 | 63 | $3,432 |
| Xtandi Enzalutamide | 153 | 153 | 31 | $2.1M |
| Nubeqa Darolutamide | 151 | 151 | 31 | $2.0M |
| Prednisone Generic | 108 | 110 | 21 | $521 |
| Abiraterone Acetate Generic | 91 | 91 | 14 | $148K |
| Erleada Apalutamide | 57 | 59 | 11 | $859K |
| Myrbetriq Mirabegron | 54 | 114 | 21 | $49K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 33 | 81 | 15 | $1,180 |
| Talzenna Talazoparib Tosylate | 29 | 29 | Under 11 | $356K |
| Gemtesa Vibegron | 25 | 53 | Under 11 | $24K |
| Tamoxifen Citrate Generic | 24 | 38 | Under 11 | $202 |
| Dexamethasone Generic | 22 | 36 | 13 | $198 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 22 | 59 | Under 11 | $634 |
Brand drugs: - claims; generic drugs: 989 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Neal Shore $514K ($448K in general payments such as food, travel and fees and $66K for research) from 48 companies. The largest payer was Janssen Research & Development, LLC with $155K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Research & Development, LLC JNJ | 8 | $155K |
| Pfizer Inc. PFE | 79 | $97K |
| AstraZeneca Pharmaceuticals LP AZN | 32 | $76K |
| Novartis Pharmaceuticals Corporation NVS | 18 | $41K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $24K |
| E.R. Squibb & Sons, L.L.C. BMY | 29 | $17K |
| Janssen Scientific Affairs, LLC JNJ | 3 | $17K |
| AstraZeneca UK Limited AZN | 8 | $15K |
| Sumitomo Pharma America, Inc. 4506.T | 6 | $13K |
| Urogen Pharma, Inc. URGN | 1 | $12K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.